Download in electronic PDF format for $65

Abstract:  Domperidone is a prokinetic agent used as a second-line treatment option for gastroparesis in those unable to tolerate metoclopramide. Via inhibition of dopamine- 2 receptors within the gastrointestinal tract and various parts of the central and peripheral nervous system, domperidone helps to facilitate peristalsis and gastric emptying. A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation. In the U.S., domperidone is currently not U.S. Food and Drug Administration approved due to various case reports and literature associating the risks of sudden cardiac death and ventricular arrhythmia with the use of domperidone. Despite the evidence against the use of domperidone, it is still being widely used in Canada and Europe for both gastroparesis and to induce milk let-down. This article is a literature review intending to assess the risks associated with the use of domperidone in gastroparesis and lactation.

Related Keywords: Ha Phan, Annie DeReese, PharmD, RPh, A.J. Day, PharmD, RPh, Maria Calvalho, PharmD, MRPharmS, PhD, domperidone, prokinetic agent, dopamine 2 receptors, prolactinemia, lactation induction, U.S. Food and Drug Administration, FDA, sudden cardiac death, arrhythmia, gastrointestinal motility, prolonged QTc interval, breast milk

Related Categories: GASTROENTEROLOGY, ADVERSE DRUG EVENTS, CARDIOLOGY, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, LITERATURE REVIEW

Printer-Friendly Version